Engitix Collaborates With Dompé On Fibrosis And Cancer As It Eyes The Clinic
The UK biotech has struck up an unusual deal with its new investor that lets it retain control over its assets, as it raises $54m in a series A.
You may also be interested in...
Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.
Asia Deal Watch: Takeda Will Employ Engitix’s ECM Tech In Liver Fibrosis Indications
Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.